The Alzheimer’s disease (AD) community has been shaken by disappointing clinical trials for treatments created to slow or stop disease progression.

Nonetheless, there remain reasons for optimism based on an improved understanding of the pathophysiology and course of the disease and increasing collaboration among industry, academia, and regulatory stakeholders. Success is expected as the field adopts trial designs and endpoints appropriate for trials targeting early stage illness.

Article P. Aisen